Callidus Biopharma Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $15M

Callidus Biopharma General Information

Description

Developer of enzyme-replacement therapies for lysosomal-storage disorders. The company is focused on drug discovery, using a novel technology platform that attaches a form of the naturally occurring Insulin-like Growth Factor (IGF-2) to enhance the targeting of the therapeutic enzymes to relevant cells in the body.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 3805 Old Easton Road
  • Doylestown, PA 18902
  • United States
+1 (215)
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Drug Discovery
Vertical(s)
Corporate Office
  • 3805 Old Easton Road
  • Doylestown, PA 18902
  • United States
+1 (215)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Callidus Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 21-Nov-2013 $15M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 12-Apr-2013 Completed Pre-Clinical Trials
To view Callidus Biopharma’s complete valuation and funding history, request access »

Callidus Biopharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Callidus Biopharma’s complete cap table history, request access »

Callidus Biopharma Patents

Callidus Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2014082080-A2 Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases Inactive 26-Nov-2012
WO-2014082080-A3 Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases Inactive 26-Nov-2012
WO-2012166653-A3 Methods for coupling targeting peptides onto recombinant lysosomal enzymes Inactive 27-May-2011
WO-2012166653-A2 Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases Inactive 27-May-2011
WO-2012071422-A2 Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins Inactive 22-Nov-2010 C07K14/47
To view Callidus Biopharma’s complete patent history, request access »

Callidus Biopharma Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
120 Capital Venture Capital Minority
WuXi Healthcare Ventures Corporate Venture Capital Minority
To view Callidus Biopharma’s complete investors history, request access »

Callidus Biopharma FAQs

  • When was Callidus Biopharma founded?

    Callidus Biopharma was founded in 2010.

  • Where is Callidus Biopharma headquartered?

    Callidus Biopharma is headquartered in Doylestown, PA.

  • What industry is Callidus Biopharma in?

    Callidus Biopharma’s primary industry is Drug Delivery.

  • Is Callidus Biopharma a private or public company?

    Callidus Biopharma is a Private company.

  • What is the current valuation of Callidus Biopharma?

    The current valuation of Callidus Biopharma is .

  • What is Callidus Biopharma’s current revenue?

    The current revenue for Callidus Biopharma is .

  • How much funding has Callidus Biopharma raised over time?

    Callidus Biopharma has raised $4.61M.

  • Who are Callidus Biopharma’s investors?

    120 Capital and WuXi Healthcare Ventures have invested in Callidus Biopharma.

  • When was Callidus Biopharma acquired?

    Callidus Biopharma was acquired on 21-Nov-2013.

  • Who acquired Callidus Biopharma?

    Callidus Biopharma was acquired by Amicus Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process